American College of Cardiology: Semaglutide Reduces COVID-19 Related Deaths in Patients With Obesity and CVD
August 31, 2024
August 31, 2024
WASHINGTON, Aug. 31 (TNSres) -- The American College of Cardiology issued the following news release:
* * *
New SELECT trial substudy finds anti-obesity drug has protective effects beyond weight loss
* * *
LONDON (Aug 30, 2024) - Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, accordi . . .
* * *
New SELECT trial substudy finds anti-obesity drug has protective effects beyond weight loss
* * *
LONDON (Aug 30, 2024) - Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, accordi . . .